Aura Renew Acq Regulatory News (ARA)

31 Aug 2006 07:01

Ardana PLC31 August 2006 US PATENT GRANTED TO ARDANA FOR TEVERELIX LA Edinburgh, UK, 31 August 2006; Ardana (LSE: ARA), the pharmaceutical companyfocused on improving human reproductive health, today announces that it has beengranted a US patent, number 7,098,305, covering the long acting formulation ofits GnRH antagonist, Teverelix (Teverelix LA). The patent is subject to a US patent term adjustment (i.e. extension), whichmeans that it is not due to expire in the US until April 2023. This patent forms part of Ardana's growing intellectual property portfolioaround its research and development activities. Teverelix is Ardana's lead development compound and is in Phase II clinicaltrials in two indications; prostate cancer and benign prostatic hyperplasia,with Phase I studies ongoing in endometriosis. For more information contact: Ardana Financial DynamicsMaureen Lindsay (corporate/financial media relations)Tel: + 44 (0) 131 226 8550 Julia Phillips/John Gilbert Tel: +44 (0)20 7831 3113 About Ardana Ardana plc is a pharmaceutical company focused on the discovery, development andmarketing of innovative products to improve human reproductive health, a $25.5billion market. Since its foundation, Ardana has maintained a broad and balanced portfolio tomanage risk and actively pursues product and technology in-licensing andoutlicensing to maintain a robust pipeline. Ardana's four lead products are summarised below: • StriantTM SR, a testosterone replacement therapy that has been launched by Ardana through its own sales force in the UK and through marketing partners in certain European countries, as a treatment for men with hypogonadism; • Teverelix LA, in development for three initial indications (prostate cancer, BPH and endometriosis); • Testosterone Cream, a trans dermal testosterone delivery system in development for the treatment of male hypogonadism, in Phase II trials; • Invicorp, an injectable combination drug treatment for erectile dysfunction, for which Ardana has marketing and manufacturing rights in Europe. In addition, Ardana has a strong portfolio of follow-on products in development. Ardana is listed on the Main Market of the London Stock Exchange. For further information please see www.ardana.co.uk This information is provided by RNS The company news service from the London Stock Exchange